Form 8.3 - Horizon Therapeutics plc

LONDON--()-- 

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

  1. KEY INFORMATION

Name of person dealing (Note 1)

Millennium International Management LP

Company dealt in

Horizon Therapeutics plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

IE00BQPVQZ61

Date of dealing

17th April 2023

  1. INTERESTS AND SHORT POSITIONS
  1. Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

4,333,298

(1.894%)

26,030

(0.011%)

(2) Derivatives (other than options)

-

-

(3) Options and agreements to purchase/sell

379,900

(0.166%)

1,252,600

(0.548%)

Total

4,713,198

(2.060%)

1,278,630

(0.559%)

b. Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

 

 

 

(2) Derivatives (other than options)

 

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

 

Ap20

  1. DEALINGS (Note 4)
  1. Purchases and sales

 

Purchase/sale

 

Number of relevant securities

 

Price per unit (USD) (Note 5)

Purchase

3

112.01

Sale

9

112.12

Purchase

1,138

111.89

Purchase

6

112.06

Purchase

1,850

111.90

Purchase

12

111.87

Purchase

1

112.01

Purchase

2,987

112.02

Sale

2,906

111.99

Sale

109

112.09

Sale

7

112.04

Sale

60

112.07

Sale

122

112.12

Sale

287

112.02

Purchase

312

111.99

Sale

31

111.99

Sale

190

112.13

Sale

800

112.06

Sale

100

112.14

Sale

18

112.10

Sale

300

112.09

Sale

100

112.11

Sale

175

112.03

Sale

115

112.08

Purchase

307

112.40

Purchase

452

112.04

Sale

3,278

112.04

Purchase

1,670

112.07

Purchase

2,391

112.01

Sale

247

112.01

Purchase

4,337

112.12

Sale

83

112.12

Purchase

10,000

112.02

Sale

3,125

112.02

Purchase

2,569

111.98

Purchase

162

111.99

Sale

1,512

111.99

Purchase

452

112.16

Sale

35

112.13

Sale

38

111.89

Purchase

2,519

112.05

Sale

732

112.05

Purchase

1,100

112.06

Sale

200

112.06

Purchase

1,700

112.14

Purchase

1,186

112.10

Sale

29

112.10

Purchase

848

112.09

Sale

4

112.09

Sale

1,271

111.97

Purchase

8,600

112.36

Sale

130

111.90

Sale

830

111.96

Sale

1,751

112.00

Sale

1,253

112.03

Purchase

314

112.08

Purchase

590

111.94

Sale

247

111.94

Sale

40

111.91

Purchase

39

111.83

Sale

30

111.92

Sale

20

111.93

Sale

720

112.01

b. Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit (USD)

(Note 5)

 

 

 

 

c. Options transactions in respect of existing relevant securities

  1. Writing, selling, purchasing or varying

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

(USD)

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

 

 

 

 

 

ii. Exercising

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

d. Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure

18th April 2023

Contact name

Sirina Kumar

Telephone number

+44 203 192 8741

If a connected EFM, name of offeree/offeror with which connected

 

If a connected EFM, state nature of connection (Note 10)

 

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making
disclosure:

Millennium International Management LP

Name of offeror/offeree in relation
to whose relevant securities the
disclosure relates:

Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of
relevant
security

Product
description
e.g. call
option

Written or
purchased

Number of
securities to
which option
or derivative
relates

Exercise
price
per unit

(USD)

Type
e.g.
American,
European
etc.

Expiry
date

IE00BQPVQZ61

Put Option

Purchased

1,100

90.00

American

5/19/2023

IE00BQPVQZ61

Call Option

Purchased

11,500

110.00

American

5/19/2023

IE00BQPVQZ61

Call Option

Written

262,400

115.00

American

5/19/2023

IE00BQPVQZ61

Call Option

Purchased

42,500

120.00

American

5/19/2023

IE00BQPVQZ61

Put Option

Purchased

55,200

110.00

American

5/19/2023

IE00BQPVQZ61

Put Option

Purchased

2,900

80.00

American

5/19/2023

IE00BQPVQZ61

Put Option

Purchased

300

80.00

American

1/17/2025

IE00BQPVQZ61

Put Option

Purchased

300

90.00

American

1/19/2024

IE00BQPVQZ61

Call Option

Purchased

1,200

110.00

American

8/18/2023

IE00BQPVQZ61

Call Option

Written

201,200

115.00

American

8/18/2023

IE00BQPVQZ61

Put Option

Written

221,000

80.00

American

8/18/2023

IE00BQPVQZ61

Put Option

Purchased

254,200

100.00

American

5/19/2023

IE00BQPVQZ61

Put Option

Purchased

3,600

105.00

American

6/16/2023

IE00BQPVQZ61

Put Option

Purchased

10,900

105.00

American

7/21/2023

IE00BQPVQZ61

Put Option

Purchased

5,200

105.00

American

4/21/2023

IE00BQPVQZ61

Call Option

Written

100,000

115.00

American

6/16/2023

IE00BQPVQZ61

Put Option

Written

103,400

85.00

American

6/16/2023

IE00BQPVQZ61

Put Option

Purchased

155,000

100.00

American

6/16/2023

IE00BQPVQZ61

Call Option

Purchased

300

110.00

American

6/16/2023

IE00BQPVQZ61

Put Option

Purchased

300

110.00

American

6/16/2023

IE00BQPVQZ61

Put Option

Purchased

200,000

100.00

American

8/18/2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

 

 

 

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Category Code: RET
Sequence Number: 1081967
Time of Receipt (offset from UTC): 20230418T132747+0100

Contacts

Millennium Partners, L.P.

Contacts

Millennium Partners, L.P.